🧬 Article Summary
A recent study showed that modern oral GLP-1 medicines may reduce the desire to eat by modifying the activity of reward circuits in the brain, not just through traditional appetite control. These findings open new horizons for understanding how these medicines affect eating behavior, and they may expand future uses to include treatments for addiction and craving disorders.
🧠 Understanding the Effect of New GLP-1 Medicines on the Brain
Medicines such as semaglutide and Ozempic are known as part of the GLP-1 family of medicines, used mainly to treat obesity and type 2 diabetes. These medicines work by reducing appetite through their effect on areas in the hypothalamus and hindbrain, which are responsible for regulating hunger and the body’s need for energy.
But what is new in the research conducted by the University of Virginia is the study of small-molecule oral GLP-1 medicines, such as orforglipron and danuglipron. This study proved that the effect of the medicines is not limited to regulating physical appetite alone, but also includes a profound modification in the brain’s reward circuits that control a person’s desire to eat for pleasure-related reasons only.
🌱 Motives for the Research and Its Importance
Small-molecule oral medicines are distinguished by the possibility of being taken as capsules instead of injections, which may make them easier and lower in cost compared with peptide medicines such as semaglutide.
As use of these medicines increases, it has become necessary to understand the neural mechanisms through which they act, especially because they may affect the brain circuits responsible for reward-related cravings, something that had not been known before.
🧪 How GLP-1 Medicines Work on Reward Circuits
In the study, the researchers used gene-editing techniques to make GLP-1 receptors in mice more similar to their human counterparts. They then gave the mice the drugs orforglipron and danuglipron, and observed the neural changes occurring in their brains.
As expected, the drug interacted with the brain regions known to regulate appetite, but what was surprising was that it also led to activation of the central amygdala, a deep brain region associated with desire and reward rather than physical hunger.
The key scientific result lies in the fact that activation of the central amygdala reduced the secretion of dopamine in the centers of the reward system while eating for pleasure, which reduces the desire for highly palatable foods.
🩺 The Difference Between Oral and Peptide GLP-1 Medicines
- Peptide medicines (such as semaglutide) control appetite through regions like the hypothalamus and hindbrain.
- Small-molecule oral medicines (such as orforglipron and danuglipron) reach deeper reward circuits in the brain, such as the central amygdala.
- Oral medicines can be taken as capsules, which contributes to ease of use and may reduce cost.
🌿 Health Importance and Future Prospects
The importance of this discovery lies in expanding our understanding of how GLP-1 medicines affect eating behavior, especially in reducing hedonic feeding, meaning eating for pleasure rather than to meet the body’s energy needs.
This indicates the possibility of using these medicines in treating disorders related to desire and reward not only in the field of food, but perhaps in cases of drug use or other disorders associated with addiction to various substances.
🧬 The Future of Research and Medical Applications
- Future studies confirming the extent of the medicines’ effect on substance use disorder.
- A deeper understanding of the neural mechanisms that control reward-related cravings.
- Developing effective, more affordable medicines that are easy to take orally.
⚠️ Final Notes
The study, supported by the United States National Institutes of Health NIH, especially with funding from institutes specialized in nervous system disorders, has not yet been conducted within the framework of clinical trials approved by the United States Food and Drug Administration FDA with regard to the regulatory approvals specific to these indications.
Therefore, it is important to treat the findings as an important scientific research step, without jumping to therapeutic uses before more studies and official evaluations.
In conclusion, this research is an important addition to understanding how modern GLP-1 medicines work, and it provides a scientific basis for expanding their use in the future, which may positively affect public health and the management of consumption disorders and reward-related behaviors.
📚 Related articles
Discover more from Mohdbali
Subscribe to get the latest posts sent to your email.
